Return to homepagePandemic Pact

Etiology and outcome of MIS-C

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3U19AI144306-02S1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $1,491,907

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    Betty Diamond

  • Research Location

    United States of America

  • Lead Research Institution

    Feinstein Institute For Medical Research

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adolescent (13 years to 17 years), Children (1 year to 12 years)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Abstract: This proposal seeks to test two hypotheses regarding the Multisystem Inflammatory Syndrome(MIS-C) recently identified in children and young adults infected with SARS-CoV-2. Wehypothesize that there is a spectrum of disease from severe acute disease to MIS-C. SevereCov acute disease is associated with low interferon production, poor control of virus and agerminal center derived antibody response to the virus leading to long term immunity while MIS-C is associated with high interferon, efficient control of virus, but an extrafollicular derivedantibody response with poor long term immunity. We will test this hypothesis through a geneticanalysis, analysis of serum cytokines and analysis of anti-viral antibodies. We also hypothesizethat plasma metabolic profile of subjects with MIS-C will predict short term cardiac dysfunctionand long term cardiac damage.